MXPA01013420A - Agentes terapeuticos. - Google Patents

Agentes terapeuticos.

Info

Publication number
MXPA01013420A
MXPA01013420A MXPA01013420A MXPA01013420A MXPA01013420A MX PA01013420 A MXPA01013420 A MX PA01013420A MX PA01013420 A MXPA01013420 A MX PA01013420A MX PA01013420 A MXPA01013420 A MX PA01013420A MX PA01013420 A MXPA01013420 A MX PA01013420A
Authority
MX
Mexico
Prior art keywords
alkyl
tetrahydro
carbon atoms
benzothiazepine
optionally substituted
Prior art date
Application number
MXPA01013420A
Other languages
English (en)
Spanish (es)
Inventor
Ian Charles Kilpatrick
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of MXPA01013420A publication Critical patent/MXPA01013420A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
MXPA01013420A 1999-06-24 2000-06-16 Agentes terapeuticos. MXPA01013420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914745.6A GB9914745D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005541 WO2001000185A2 (en) 1999-06-24 2000-06-16 1,4-denzothiazepines to treat obesity related disorders

Publications (1)

Publication Number Publication Date
MXPA01013420A true MXPA01013420A (es) 2002-07-22

Family

ID=10855956

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01013420A MXPA01013420A (es) 1999-06-24 2000-06-16 Agentes terapeuticos.

Country Status (7)

Country Link
EP (1) EP1218010A2 (de)
JP (1) JP2003513008A (de)
AU (1) AU5973600A (de)
CA (1) CA2376023A1 (de)
GB (1) GB9914745D0 (de)
MX (1) MXPA01013420A (de)
WO (1) WO2001000185A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP5497429B2 (ja) * 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
JP2012508692A (ja) 2008-11-12 2012-04-12 シェーリング コーポレイション 脂肪酸結合タンパク質（ｆａｂｐ）の阻害薬
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
EP2708535A1 (de) 2012-05-11 2014-03-19 Les Laboratoires Servier Mittel zur Behandlung von Erkrankungen durch Modulation von Ryanodin-Rezeptoren

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361760A (en) * 1963-03-21 1968-01-02 Squibb & Sons Inc Benzothiazepines
US3794639A (en) * 1966-03-10 1974-02-26 Squibb & Sons Inc Benzoxazepines and benzothiazepines
JP2871811B2 (ja) * 1990-02-28 1999-03-17 サントリー株式会社 縮合７員環系化合物
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
JP3093419B2 (ja) * 1992-03-30 2000-10-03 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
ES2113081T3 (es) * 1992-11-09 1998-04-16 Knoll Ag 1,4-benzotiazepinas utiles como agentes neurologicos.
US5610153A (en) * 1992-12-11 1997-03-11 Ciba-Geigy Corporation Benzazepinone derivatives
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) * 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
DE69815180T2 (de) * 1997-03-14 2004-04-29 Aventis Pharma Deutschland Gmbh Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
CN1213036C (zh) * 1997-08-22 2005-08-03 科研制药株式会社 新的酰胺类衍生物

Also Published As

Publication number Publication date
GB9914745D0 (en) 1999-08-25
CA2376023A1 (en) 2001-01-04
WO2001000185A2 (en) 2001-01-04
JP2003513008A (ja) 2003-04-08
EP1218010A2 (de) 2002-07-03
AU5973600A (en) 2001-01-31
WO2001000185A3 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
US5942549A (en) Improving glucose tolerance
EP0236684B1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
US20020165261A1 (en) Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20050261356A1 (en) Methods and compositions for the treatment of chronic lymphocytic leukemia
MXPA02001649A (es) Uso de inhibidores de monoamina oxidasa para la elaboracion de farmacos destinados al tratamiento de la obesidad.
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
AU758181B2 (en) Therapeutic agents
JPH0637395B2 (ja) ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤
CZ255097A3 (en) Transdermal preparation
MXPA01013420A (es) Agentes terapeuticos.
CA2367021A1 (en) Method of controlling weight gain associated with therapeutic drugs
WO1995028933A1 (en) Use of arylpiperazine derivatives for the treatment of parkinson's disease and psychosis
TW200418455A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
MXPA01013421A (es) Agentes terapeuticos.
EP0874840A1 (de) Dibenzothiepin derivate und pharmazeutische zusammenstellungen
US20030008897A1 (en) Method of controlling weight gain associated with therapeutic drugs
EP0946181B1 (de) Verwendung von 2-(2-morpholinophenyl)guanidinderivate zur behandlung von diabetes-komplikationen
WO2007093587A1 (en) Use of r-(-)-2,4-diamino-5-(2, 3-dichlorophenyl)-6-fluoromethyl pyrimidine for the treatment of psychotic disorders
CA2460360A1 (en) Systematical administration of some oxazolidinones, e.g. linezolid, for the treatment for ocular infections
GB2319961A (en) Pharmaceutical composition for treatment of restenosis
CA2501093A1 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain